콘텐츠로 건너뛰기
주식/증권 📈 긍정적

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?

요약

This year, the biotech stock has underperformed both the Nasdaq Biotechnology Index and the S&P 500.